Merck’s Cholesterol Pill Cuts the Bad Number 60%. No Needle.

The FDA just approved the first oral PCSK9 inhibitor. It is the cheapest kind of blockbuster — the science was already proven, the market already exists, and the only thing the patient notices is that nothing gets injected.

By Sean Anees Saifi · Capital Wealth · Published Thursday, July 17, 2026 · Source: The Wall Street Journal, July 17, 2026

Key Points

The FDA approved Merck’s Lipfendra — the first oral PCSK9 inhibitor on the market.
It cuts bad cholesterol by roughly 60%, versus 20–30% for statins alone.
Wall Street pencils in $5 billion-plus in peak annual sales.
Rival PCSK9 drugs — Amgen’s Repatha, Regeneron’s Praluent — require a shot every two weeks.
A market this big feeds three winners, not one — so we are not rotating the sleeve.

60%

cut in bad cholesterol from Lipfendra

20–30%

what statins alone typically deliver

$5B+

Street estimate for peak annual sales

A single white pill on a dark counter, lit like a specimen

In one line: Merck turned the strongest class of cholesterol drug into a pill, and the Street sees $5 billion-plus in peak sales. We treat it as validation of the whole category, not a rotation bet.

There is a category of drug approval that makes a cardiologist put down the sandwich, and Thursday produced one. The FDA approved Merck’s (MRK) Lipfendra — the first oral PCSK9 inhibitor to reach the market. A pill that does what, until now, required a needle.

Quick translation. A PCSK9 inhibitor blocks a protein so your liver can pull more bad cholesterol out of your blood. A statin — the standard cholesterol pill for decades — works differently and does less.

The number that matters

Lipfendra cuts bad cholesterol by roughly 60%. Statins alone get you 20–30%. That gap is the whole headline.

The Street has penciled in $5 billion-plus in peak annual sales. That is blockbuster territory, and the path there is unusually clear.

Until now, the PCSK9 drugs that deliver a 60% reduction — Amgen’s (AMGN) Repatha and Regeneron’s (REGN) Praluent — came only as injectables. A shot, every two weeks, forever.

Patients will do almost anything to avoid that. Ask any doctor who has watched a prescription go unfilled because it came with a needle attached.

A pill removes the excuse. It slides into the routine next to the vitamins, and adherence — actually taking the medicine you were prescribed — stops being a battle. In a chronic condition, adherence is the whole game.

Why convenience wins

Merck’s bet is simple. Price the pill competitively with the injectables, and let it win on the one dimension patients actually feel.

A first-in-class oral drug in a proven category is the cheapest kind of blockbuster. The science is validated. The market already exists. The only innovation the patient notices is that nothing gets injected.

There is no new biology to prove here, and no new market to build. The lipid business has been minting money since the first statin came off the line decades ago. Your arteries, as ever, remain one of the great addressable markets.

One market, three winners

Here is the part worth saying plainly. A category this large does not crown one winner. It feeds three.

Amgen and Regeneron keep the patients who are already settled on injectables and the doctors who trust them. Merck opens the much larger pool of people who said no to the needle. Competition on price and convenience grows the whole pie.

That is why the answer here is not a dramatic rotation. Big pharma is a portfolio business — no single pill makes or breaks a company with a pipeline as deep as Merck’s. Rotating a whole sleeve toward one headline is how investors turn good news into bad decisions.

So MRK stays reinforced in the Capital Wealth Growth Portfolio, for the right reason: low-risk, high-durability revenue in a validated category. AMGN and REGN stay held on their own merits, because the lipid market is large enough for all three.

We treat the Lipfendra approval as validation of the category, not an invitation to concentrate. Healthcare remains what it has always been for us: a core defensive sleeve that occasionally hands you a blockbuster for free.

What It Means For Your Portfolio

Hold — category validated

MRK stays reinforced; AMGN and REGN stay held — the lipid market is big enough for all three.

A first-in-class oral drug in a validated category is low-risk, durable revenue, and that is why Merck keeps its place in the Capital Wealth Growth Portfolio. We do not rotate the healthcare sleeve toward one name on one approval — big pharma is a portfolio business. The approval validates the whole category, and healthcare stays a core defensive sleeve.